title: What does a modified-Fibonacci dose-escalation actually correspond to?
abstract: BACKGROUND
  In most phase I oncology trials, it is often stated that the dose increments follow a "modified-Fibonacci sequence". This term, however, is vague.
  
  
  METHODS
  To better characterize this sequence, we reviewed 81 phase I trials based on this concept.
  
  
  RESULTS
  Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35…. The "modified Fibonacci-sequence" gathers heterogeneous variation of the genuine sequence, which does not tend to a constant number at higher dose-levels.
  
  
  CONCLUSIONS
  This confusing term should be avoided.
authors: Methodology and Biostatistics Unit, Centre Oscar Lambret, 3 rue Frederic Combemale, 59020, Lille cedex, France. n-penel@o-lambret.fr
authors: Nicolas
authors: N
authors: Penel
authors: Andrew
authors: A
authors: Kramar
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002985:Clinical Protocols; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D006801:Humans; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents